CHEMOTHERAPY INDUCED THROMBOCYTOPENIA THERAPEUTICS MARKET ANALYSIS

Market Challenges And Opportunities

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Drivers

• Increasing Research and Development Activities: Continued investments in research and development to develop innovative thrombocytopenia therapeutics can drive the market growth. Numerous clinical trials are conducted to evaluate the safety and efficacy of potential CIT treatments. These trials may involve novel drugs, combinations of drugs, or modifications to existing treatments. For instance, according to clinical trials.gov, in June 2022, Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that the first patient has been dosed with SCB-219M, a novel thrombopoietin receptor agonist (TPO-RA) mimetic Fc-fusion protein, in a Phase 1 clinical trial to assess the safety, tolerability, immunogenicity, pharmacokinetics, and efficacy of SCB-219M in in cancer patients with chemotherapy-induced thrombocytopenia (CIT). Clover Biopharmaceuticals, Ltd. gained IND clearance from the Center for Drug Evaluation (CDE) for SCB-219M as a Class I novel medication in December 2021.
• Rising Cases of Cancer: Dynamically surging cases of cancer have increased the number of chemotherapy procedures, which is expected to drive the growth of global chemotherapy-induced thrombocytopenia therapeutics market during the forecast period. For instance, according to Centers for Disease Control and Prevention, in the U.S., in 2020, 1,603,844 new cancer cases were reported and 602,347 people died of cancer. For every 100,000 people, 403 new cancer cases were reported and 144 people died of cancer.

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Cross Sectional Analysis

Among the distribution channel segment, the hospital pharmacies segment is expected to be dominant in the Asia Pacific region owing to the increasing launch of hospital pharmacies. For instance, on September 26, 2023, the Lilavati Hospital, a private hospital in Mumbai, India, launched a chain of Lilavati Pharmacy outlets around India. The Lilavati Pharmacy chain will also launch a community wellness programs. Customers will be able to consult with a doctor at the drugstore and receive proper treatment.

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market: Restraint

• Lack of Approved Drugs: Growth of the global chemotherapy-induced thrombocytopenia therapeutics market is expected to be hampered over the forecast period owing to the lack of approved drugs or therapeutics for the treatment of chemotherapy-induced thrombocytopenia. For instance, currently, Oprelvekin-recombinant interleukin-11 (IL-11) is the only thrombopoietic agent which was approved by the U.S. Food and Drug Administration (FDA) in 1998 for the treatment of chemotherapy-induced thrombocytopenia. It is indicated for adults with solid tumors and lymphomas associated with severe chemotherapy-induced thrombocytopenia.